Fennec Pharmaceuticals Inc. (FENC): Price and Financial Metrics

Fennec Pharmaceuticals Inc. (FENC): $9.55

0.20 (+2.14%)

POWR Rating

Component Grades














  • Sentiment is the dimension where FENC ranks best; there it ranks ahead of 94.42% of US stocks.
  • The strongest trend for FENC is in Momentum, which has been heading down over the past 48 weeks.
  • FENC ranks lowest in Momentum; there it ranks in the 9th percentile.

FENC Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for FENC is 0.01 -- better than just 7.31% of US stocks.
  • With a price/sales ratio of 1,438.03, Fennec Pharmaceuticals Inc has a higher such ratio than 99.48% of stocks in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.13 for Fennec Pharmaceuticals Inc; that's greater than it is for just 9.19% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Fennec Pharmaceuticals Inc are MOTS, SUMO, NTNX, FEYE, and ZUO.
  • FENC's SEC filings can be seen here. And to visit Fennec Pharmaceuticals Inc's official web site, go to www.fennecpharma.com.

FENC Valuation Summary

  • In comparison to the median Healthcare stock, FENC's price/earnings ratio is 130.96% lower, now standing at -11.3.
  • FENC's price/earnings ratio has moved down 3.7 over the prior 203 months.
  • FENC's price/sales ratio has moved NA NA over the prior 203 months.

Below are key valuation metrics over time for FENC.

Stock Date P/S P/B P/E EV/EBIT
FENC 2021-08-31 1211.8 9.2 -11.3 -10.1
FENC 2021-08-30 1202.4 9.2 -11.2 -10.0
FENC 2021-08-27 1247.1 9.5 -11.7 -10.4
FENC 2021-08-26 1219.4 9.3 -11.4 -10.2
FENC 2021-08-25 1222.4 9.3 -11.4 -10.2
FENC 2021-08-24 1181.2 9.0 -11.0 -9.8

FENC Growth Metrics

  • Its 3 year net cashflow from operations growth rate is now at -341.48%.
  • Its 2 year price growth rate is now at -40.16%.
  • The year over year net cashflow from operations growth rate now stands at -49.46%.
Over the past 70 months, FENC's revenue has gone up $170,000.

The table below shows FENC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 0.17 -16.749 -18.172
2021-03-31 0.17 -15.439 -19.016
2020-12-31 0.17 -15.595 -18.109
2020-09-30 0 -13.901 -18.481
2020-06-30 0 -10.69 -14.09
2020-03-31 0 -10.33 -13.975

FENC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FENC has a Quality Grade of D, ranking ahead of 22.53% of graded US stocks.
  • FENC's asset turnover comes in at 0.006 -- ranking 402nd of 677 Pharmaceutical Products stocks.
  • AUPH, APLS, and CARA are the stocks whose asset turnover ratios are most correlated with FENC.

The table below shows FENC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.006 1 642.938
2021-03-31 0.005 1 9.909
2020-12-31 0.006 1 9.925
2020-09-30 0.000 NA 9.479
2020-06-30 0.000 NA 9.306
2020-03-31 0.000 NA 12.541

FENC Price Target

For more insight on analysts targets of FENC, see our FENC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.60 Average Broker Recommendation 1.4 (Strong Buy)

FENC Stock Price Chart Interactive Chart >

Price chart for FENC

FENC Price/Volume Stats

Current price $9.55 52-week high $9.83
Prev. close $9.35 52-week low $5.69
Day low $9.35 Volume 25,201
Day high $9.83 Avg. volume 109,111
50-day MA $7.61 Dividend yield N/A
200-day MA $7.22 Market Cap 248.37M

Fennec Pharmaceuticals Inc. (FENC) Company Bio

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was founded in 1996 and is based in Research Triangle Park, North Carolina.

FENC Latest News Stream

Event/Time News Detail
Loading, please wait...

FENC Latest Social Stream

Loading social stream, please wait...

View Full FENC Social Stream

Latest FENC News From Around the Web

Below are the latest news stories about Fennec Pharmaceuticals Inc that investors may wish to consider to help them evaluate FENC as an investment opportunity.

Fennec Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update

~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~ ~ If Approved by the FDA, PEDMARK™ Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ Company Has Approximately $27 Million in Cash and Cash Equivalents ~ RESEARCH TRIANGLE PARK, N.C., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique for

Yahoo | August 10, 2021

Is Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Popular Amongst Institutions?

If you want to know who really controls Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ), then you'll have to look at the...

Yahoo | August 2, 2021

Fennec Announces Results of Annual Meeting

RESEARCH TRIANGLE PARK, N.C., June 29, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated May 14, 2021 for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held in Irvine, California and online on June 29, 2021. Detailed results of the vote for the election of directors are set out below: Name of

Yahoo | June 29, 2021

Fennec Pharmaceuticals Announces Amendment to Increase Existing Senior Debt Facility

RESEARCH TRIANGLE PARK, N.C., June 24, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients with localized, non-metastatic solid tumors, today announced an amendment to its existing senior debt facility with the Life Sciences Group at Bridge Bank increasing the size of the facility

Yahoo | June 24, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning!

William White on InvestorPlace | June 22, 2021

Read More 'FENC' Stories Here

FENC Price Returns

1-mo 17.18%
3-mo 31.00%
6-mo 52.43%
1-year 63.53%
3-year 16.46%
5-year N/A
YTD 28.19%
2020 14.79%
2019 1.72%
2018 -36.33%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.2161 seconds.